Press Releases

Circassia’s ToleroMune Cat Allergy Treatment Maintains Symptom Improvement Two Years After Start of Short-Course Therapy

OXFORD, UK and SAN ANTONIO, USA – 25 February 2013 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course...

View details

Circassia Receives Outstanding Abstract Awards at 2012 World Allergy Organization International Scientific Conference

OXFORD, UK – 10th December 2012 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the receipt of two Outstanding Abstract Awards at the 2012 World Allergy Organization International Scientific Conference (WISC)....

View details

Circassia Appoints Dr Jean-Jacques Garaud to its Board of Directors

OXFORD, UK – 6 December 2012 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Dr Jean-Jacques Garaud MD to its Board of Directors. Dr Garaud has extensive pharmaceutical...

View details

Circassia Initiates Pivotal Phase 3 ToleroMune® Trial in Cat Allergen-Induced Rhinoconjunctivitis

OXFORD, UK – 4 October 2012 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune® cat allergy treatment for cat...

View details

Circassia Announces Publication of ToleroMune® Cat Allergy Treatment Clinical Results in Journal of Allergy and Clinical Immunology

OXFORD, UK – 27 September 2012 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the publication of positive phase II results with its ToleroMune® cat allergy treatment in the Journal of...

View details

Circassia Appoints Stewart Sharpe as Vice President Commercial Operations

OXFORD, UK – 18 September 2012 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Stewart Sharpe to the newly-created position of Vice President, Commercial Operations. Mr Sharpe, who...

View details

Circassia Appoints Dr Brett Haumann as Chief Medical Officer

OXFORD, UK – 11 September 2012 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Dr Brett Haumann as Chief Medical Officer. Dr Haumann joins Circassia from GlaxoSmithKline where...

View details

Circassia’s Canadian Joint Venture With McMaster University Initiates Two Clinical Studies to Explore Biomarkers of ToleroMune® Treatment Effectiveness

Oxford, UK – 9 August 2012 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its Canadian joint venture with McMaster University, Adiga Life Sciences Inc, has initiated two clinical studies...

View details

NIH Awards $6.4 Million to Professor Mark Larché to Investigate Mechanisms of Allergy Tolerance Generated by Circassia’s ToleroMune® Treatment

OXFORD, UK – 7 June 2012 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the United States’ National Institutes of Health (NIH) has awarded a $6.4 million grant to Professor...

View details

Circassia Draws £35 Million ($56 Million) From Investors After Meeting Key Development Milestones and Completes Additional £12 Million ($19 Million) Fundraising for Late-stage Development of Allergy Product Pipeline

OXFORD, UK – 23 April 2012 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has received the second tranche totalling £35 million ($56 million) from its fundraising completed in...

View details